Compare IDEXX Laboratories, Inc. (IDXX) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs PulteGroup, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $572.92 (market cap $46.22B), while PulteGroup, Inc. trades at $129.65 (market cap $25.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | PHM | |
|---|---|---|
Market Cap | $46.22B | $25.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $142.56 |
52-Week Low | $526.44 | $110.11 |
Enterprise Value | $47.12B | $25.64B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
PulteGroup (PHM) trades at $129.72, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.20. The company reported Q2 2026 earnings of $2.48 per share, beating estimates, but revenue and margins have softened amid housing market pressures. Recent news highlights operational expansion into Northwest Florida and recognition as a Great Place to Work.
The outlook is mixed: strong cash flow, a solid balance sheet, and share buybacks support the stock, but declining net income margins and affordability challenges pose headwinds. With 43% of analysts rating it a buy, the stock offers moderate upside potential balanced against cyclical housing risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
